CDTX - CIDARA Therapeutics ALERT: Bragar Eagel & Squire P.C. is Investigating Cidara Therapeutics Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cidara Therapeutics, Inc. ("Cidara Therapeutics" or the "Company") (NASDAQ:CDTX) on behalf of Cidara Therapeutics stockholders. Our investigation concerns whether Cidara Therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On April 16, 2024, Cidara Therapeutics filed a current report on Form 8-K with the SEC. In this 8-K, Cidara Therapeutics announced that it's "previously issued audited consolidated financial statements for the fiscal years ended December 31, 2021 and 2022 included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, ...